<DOC>
	<DOCNO>NCT01798901</DOCNO>
	<brief_summary>This phase I trial study side effect best dose AR-42 give together decitabine treat patient acute myeloid leukemia . AR-42 may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , decitabine , work different way stop growth cancer cell , either kill cell stop divide . Giving AR-42 together decitabine may kill cancer cell .</brief_summary>
	<brief_title>AR-42 Decitabine Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine biologic effective tolerable dose ( BETD ) AR-42 ( histone deacetylase [ HDAC ] inhibitor AR-42 ) combination 10 day schedule decitabine acute myeloid leukemia ( AML ) adult ( Stratum 1 ) child ( Stratum 2 ) . II . To define specific toxicity dose limit toxicity ( DLT ) AR-42 combination 10 day schedule decitabine adult child . SECONDARY OBJECTIVES : I . To describe biologic activity combination AR-42 decitabine ( change micro ribonucleic acid [ RNA ] [ miR ] -29b expression ; specificity protein 1 [ Sp1 ] , deoxyribonucleic acid [ DNA ] ( cytosine-5- ) -methyltransferase [ DNMT ] 1 , 3A 3B , KIT FMS-like tyrosine kinase 3 [ FLT3 ] RNA protein level ) . II . To provide preliminary data clinical response combination AR-42 decitabine adult child . III . To provide preliminary data correlation biologic endpoint clinical response ( particularly miR-29b expression ) . OUTLINE : This dose-escalation study HDAC inhibitor AR-42 . INDUCTION THERAPY : Patients receive HDAC inhibitor AR-42 orally ( PO ) daily day 1 , 3 , 5 1 , 3 , 4 , 5 decitabine intravenously ( IV ) 1 hour day 6-15 . Treatment repeat every 28 day 3 course absence disease progression unacceptable toxicity . MAINTENANCE THERAPY : Patients achieve complete remission ( CR ) morphologic CR incomplete blood count recovery ( CRi ) receive HDAC inhibitor AR-42 Induction Therapy decitabine IV 1 hour day 6-10 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Adult patient ( stratum 1 ) must age &gt; = 18 relapse refractory acute myeloid leukemia ( AML ) age &gt; = 60 previously untreated AML candidate refuse standard/conventional induction chemotherapy ( e.g . 7+3 combination cytarabine anthracycline ) ; pediatric patient , age 3 &lt; 18 year ( stratum 2 ) eligible AML second relapse refractory disease Patients secondary AML therapy related disease ( tAML ) eligible Patients receive decitabine 5azacitidine prior treatment myelodysplastic syndrome ( MDS ) ( AML ) remain eligible dose escalation phase study ; however , neither agent permit within 3 month study entry ; patient receive prior decitabine 5 azacitidine exclude expansion phase trial If patient comorbid medical illness , life expectancy attribute must great 6 month Performance status : Adults ( &gt; = 18 year ) must Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 ; pediatric patient ( &lt; 18 year ) must least Lansky &gt; 50 % Total bilirubin &lt; 2.0 mg/dL Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) &lt; 2.5 X institutional upper limit normal Creatinine &lt; 2.0 mg/dL ( adults &gt; 18 year ) ; &lt; 1.3 x upper limit normal age ( pediatric patient &lt; 18 year ) New York Heart Association ( NYHA ) congestive heart failure ( CHF ) class II better The effect decitabine AR42 develop human fetus recommend therapeutic dose unknown ; reason , men woman must agree use adequate contraception ( barrier method birth control ; abstinence ) prior study entry duration study participation ; patient agree , patient eligible ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability understand willingness sign write informed consent document Patients must recover toxicity prior therapy less grade 2 Patients chemotherapy radiotherapy within 2 week ( 6 week nitrosoureas mitomycin C ) prior enter study ; hydroxyurea may administer control leukocytosis pretreatment cycle 1 Patients receive investigational agent patient receive investigational agent within 28 day enrollment Patients active central nervous system disease single granulocytic sarcoma sole site disease Patients history allergic reaction attribute compound similar chemical biologic composition decitabine AR42 manage oral antihistamine , antipyretic ( ie . acetaminophen ) low dose corticosteroid ( &lt; 10 mg oral prednisone equivalent corticosteroid ) Uncontrolled intercurrent illness include , limited , symptomatic congestive heart failure , unstable angina pectoris , serious cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement ; infection common feature AML , patient active infection permit enroll provide infection control ; myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) class III IV heart failure , uncontrolled angina , uncontrolled hypertension , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormalities Patients serious medical psychiatric illness likely interfere participation clinical study Patients know confirmed diagnosis human immunodeficiency virus ( HIV ) infection ( due concern increase toxicity regimen combination highly active antiretroviral therapy [ HAART ] ) Patients know diagnosis chronic hepatitis B infection ( ie . persistence hepatitis B surface antigen blood 6 month longer ) diagnosis hepatitis C ( ie . presence antihepatitis C ( hepatitis C virus [ HCV ] ) antibodies peripheral blood ) exclude ; patient recent diagnosis ( &lt; 6 month ) active viral hepatitis B C exclude Patients advanced malignant solid tumor time consideration enrollment trial exclude ; patient history advance malignant solid tumor , evidence disease time consideration enrollment , eligible Patients know impairment gastrointestinal ( GI ) function due GI disease inflammatory bowel disease ( Crohn 's disease , ulcerative colitis ) celiac disease , may significantly alter absorption AR42 exclude Pregnant woman woman breastfeed exclude study ; confirmation subject pregnant must establish negative serum βhuman chorionic gonadotropin ( βhCG ) pregnancy test result obtain screening ; pregnancy test require postmenopausal surgically sterilize woman Diagnosis prolong QT syndrome Patients mean correct QT interval ( QTc ) &gt; 450 msec male &gt; 470 msec female Inability swallow capsule</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>AR-42</keyword>
	<keyword>Decitabine</keyword>
</DOC>